Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

MGD010 · PRV-3279

Bispecific antibody · Immune activation, directed at CD32B (FCGR2B) (FCGR2B) and CD79B · developed by MacroGenics

Phase 1 Most advanced trial (none active)
MGNX Developer
1 Registered trials

What is MGD010?

MGD010 is a DART (Dual Affinity Re-Targeting) bispecific antibody-based molecule that binds CD32B and CD79B. It is administered as a single agent and is studied in healthy subjects.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
PRV-3279
Drug type
Bispecific antibody
Targets
CD32B (FCGR2B) (FCGR2B), CD79B
Mechanism
Immune activation, directed at CD32B (FCGR2B) (FCGR2B) and CD79B
Developer
MacroGenics (MGNX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1
UNII
OV18TY1BGB

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT02376036 Phase 1 Healthy Subjects Completed MGNX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Healthy Subjects

Other drugs acting on FCGR2B / CD79B

More from MacroGenics

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the MGNX page.

Follow MGNX, the company behind MGD010

See MGNX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

MGNX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.